PEN: מכפיל EV/EBITDA Penumbra

Penumbra, Inc. (PEN) focuses on leadership in minimally invasive thrombosis treatment through R&D and a recurring sales model for consumables. The company's robotic systems accelerate clot removal, and Adam Elsesser's team enjoys strong investor confidence. The company's EV/EBITDA ratio on the GURU.Markets base chart reflects the market valuation, with the parameter stabilizing at 57.86.

Investors use this metric to determine the fair value of a business while accounting for its debt load. The metric relates the enterprise value (EV) to its earnings before interest, taxes, depreciation, and amortization (EBITDA). Trends in the EV/EBITDA multiple valuation help identify whether an asset is undervalued relative to its ability to generate cash flow. For Penumbra, Inc. (PEN), such a valuation is supported by technological superiority in the thrombectomy segment and high surgeon loyalty.